Cargando…

Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi

The Covid-19 associated mucormycosis (CAM) is an emerging disease affecting immunocompromised patients. Prevention of such infections using probiotics and their metabolites persist as effective therapeutic agents. Therefore, the present study emphasizes on assessment of their efficacy and safety. Sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunavath, Ravikumar, Mohammad, Saddam Hussain, Bhukya, Kiran Kumar, Barigela, Anuradha, Banoth, Chandrasekhar, Banothu, Anil Kumar, Bhukya, Bhima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062613/
https://www.ncbi.nlm.nih.gov/pubmed/36996100
http://dx.doi.org/10.1371/journal.pone.0279118
_version_ 1785017533025222656
author Lunavath, Ravikumar
Mohammad, Saddam Hussain
Bhukya, Kiran Kumar
Barigela, Anuradha
Banoth, Chandrasekhar
Banothu, Anil Kumar
Bhukya, Bhima
author_facet Lunavath, Ravikumar
Mohammad, Saddam Hussain
Bhukya, Kiran Kumar
Barigela, Anuradha
Banoth, Chandrasekhar
Banothu, Anil Kumar
Bhukya, Bhima
author_sort Lunavath, Ravikumar
collection PubMed
description The Covid-19 associated mucormycosis (CAM) is an emerging disease affecting immunocompromised patients. Prevention of such infections using probiotics and their metabolites persist as effective therapeutic agents. Therefore, the present study emphasizes on assessment of their efficacy and safety. Samples from different sources like human milk, honey bee intestine, toddy, and dairy milk were collected, screened and characterized for potential probiotic lactic acid bacteria (LAB) and their metabolites to be used as effective antimicrobial agents to curtail CAM. Three isolates were selected based on probiotic properties and characterized as Lactobacillus pentosus BMOBR013, Lactobacillus pentosus BMOBR061 and Pediococcus acidilactici BMOBR041 by 16S rRNA sequencing and MALDI TOF-MS. The antimicrobial activity against standard bacterial pathogens showed ˃9 mm zone of inhibition. Furthermore, the antifungal activity of three isolates was tested against Aspergillus flavus MTCC 2788, Fusarium oxysporum, Candida albicans and Candida tropicalis where the results showed significant inhibition of each fungal strain. Further studies were carried out on lethal fungal pathogens like Rhizopus sp. and two Mucor sp. which are associated with post Covid-19 infection in immunosuppressed diabetic patients. Our studies on CAM inhibitory effect of LAB revealed the efficient inhibition against Rhizopus sp. and two Mucor sp. The cell free supernatants of three LAB showed varied inhibitory activity against these fungi. Following the antimicrobial activity, the antagonistic metabolite 3-Phenyllactic acid (PLA) in culture supernatant was quantified and characterized by HPLC and LC-MS using standard PLA (Sigma Aldrich). The isolate L. pentosus BMOBR013 produced highest PLA (0.441 g/L), followed by P. acidilactici BMOBR041 (0.294 g/L) and L. pentosus BMOBR061 (0.165 g/L). The minimum inhibitory concentration of HPLC eluted PLA on the Rhizopus sp. and two Mucor sp. was found to be 180 mg/ml which was further confirmed by inhibition of total mycelia under live cell imaging microscope.
format Online
Article
Text
id pubmed-10062613
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-100626132023-03-31 Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi Lunavath, Ravikumar Mohammad, Saddam Hussain Bhukya, Kiran Kumar Barigela, Anuradha Banoth, Chandrasekhar Banothu, Anil Kumar Bhukya, Bhima PLoS One Research Article The Covid-19 associated mucormycosis (CAM) is an emerging disease affecting immunocompromised patients. Prevention of such infections using probiotics and their metabolites persist as effective therapeutic agents. Therefore, the present study emphasizes on assessment of their efficacy and safety. Samples from different sources like human milk, honey bee intestine, toddy, and dairy milk were collected, screened and characterized for potential probiotic lactic acid bacteria (LAB) and their metabolites to be used as effective antimicrobial agents to curtail CAM. Three isolates were selected based on probiotic properties and characterized as Lactobacillus pentosus BMOBR013, Lactobacillus pentosus BMOBR061 and Pediococcus acidilactici BMOBR041 by 16S rRNA sequencing and MALDI TOF-MS. The antimicrobial activity against standard bacterial pathogens showed ˃9 mm zone of inhibition. Furthermore, the antifungal activity of three isolates was tested against Aspergillus flavus MTCC 2788, Fusarium oxysporum, Candida albicans and Candida tropicalis where the results showed significant inhibition of each fungal strain. Further studies were carried out on lethal fungal pathogens like Rhizopus sp. and two Mucor sp. which are associated with post Covid-19 infection in immunosuppressed diabetic patients. Our studies on CAM inhibitory effect of LAB revealed the efficient inhibition against Rhizopus sp. and two Mucor sp. The cell free supernatants of three LAB showed varied inhibitory activity against these fungi. Following the antimicrobial activity, the antagonistic metabolite 3-Phenyllactic acid (PLA) in culture supernatant was quantified and characterized by HPLC and LC-MS using standard PLA (Sigma Aldrich). The isolate L. pentosus BMOBR013 produced highest PLA (0.441 g/L), followed by P. acidilactici BMOBR041 (0.294 g/L) and L. pentosus BMOBR061 (0.165 g/L). The minimum inhibitory concentration of HPLC eluted PLA on the Rhizopus sp. and two Mucor sp. was found to be 180 mg/ml which was further confirmed by inhibition of total mycelia under live cell imaging microscope. Public Library of Science 2023-03-30 /pmc/articles/PMC10062613/ /pubmed/36996100 http://dx.doi.org/10.1371/journal.pone.0279118 Text en © 2023 Lunavath et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lunavath, Ravikumar
Mohammad, Saddam Hussain
Bhukya, Kiran Kumar
Barigela, Anuradha
Banoth, Chandrasekhar
Banothu, Anil Kumar
Bhukya, Bhima
Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title_full Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title_fullStr Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title_full_unstemmed Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title_short Antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against Covid-19 associated mucormycosis causing fungi
title_sort antimycotic effect of 3-phenyllactic acid produced by probiotic bacterial isolates against covid-19 associated mucormycosis causing fungi
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10062613/
https://www.ncbi.nlm.nih.gov/pubmed/36996100
http://dx.doi.org/10.1371/journal.pone.0279118
work_keys_str_mv AT lunavathravikumar antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT mohammadsaddamhussain antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT bhukyakirankumar antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT barigelaanuradha antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT banothchandrasekhar antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT banothuanilkumar antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi
AT bhukyabhima antimycoticeffectof3phenyllacticacidproducedbyprobioticbacterialisolatesagainstcovid19associatedmucormycosiscausingfungi